• 1
    Kleihues P, Cavenee WK. Pathology and genetics. Tumours of the nervous system, World Health Organization classification of tumours. Lyon: International Agency for Research on Cancer, 2000.
  • 2
    von Diemling A, Louis DN, von Ammon K, Petersen I, Wiestler OD, Seizinger BR. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res. 1992; 52: 42774279.
  • 3
    Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994; 145: 11751190.
  • 4
    Hashimoto N, Ichikawa D, Inazawa J, et al. Frequent deletions of material from chromosome arm 1p in oligodendroglial tumors revealed by double-target in situ hybridization and microsatellite analysis. Genes Chromosomes Cancer. 1995; 14: 295300.
  • 5
    Kraus JA, Koopman J, Kaskel P, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol. 1995; 54: 9195.
  • 6
    Bello MJ, Leone PE, Vaquero J, et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer. 1995; 64: 207210.
  • 7
    Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histologic subtype. Oncogene. 1999; 18: 41444152.
  • 8
    Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol. 1988; 23: 360364.
  • 9
    Macdonald DR, Gaspar LE, Cairncross JG. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol. 1990; 27: 573574.
  • 10
    Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic astrocytomas. J Natl Cancer Inst. 1998; 90: 14731479.
  • 11
    Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arm 1p and 19q as predictor of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000; 18: 636645.
  • 12
    Hagel C, Krog B, Laas R, Stavrou DK. Prognostic relevance of TP53 mutations, p53 protein, Ki-67 index, and conventional histological grading in oligodendrogliomas. J Exp Clin Cancer Res. 1999; 18: 305309.
  • 13
    Watanabe T, Yokoo H, Yokoo M, Yonekawa Y, Kleihues P, Ohgaki H. Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol. 2001; 60: 11811189.
  • 14
    Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 2001; 7: 839845.
  • 15
    Ueki K, Nishikawa R, Nakazato Y, et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res. 2002; 8: 196201.
  • 16
    Ishino S, Hashimoto N, Inazawa J, et al. Loss of material from chromosome arm 1p during malignant progression of meningioma revealed by fluorescence in situ hybridization. Cancer. 1998; 83: 360366.
  • 17
    Murakami M, Hashimoto N, Takahashi Y, Hosokawa Y, Inazawa J, Mineura K. A consistent region of deletion on 1p36 in meningiomas: identification and relation to malignant progression. Cancer Genet Cytogenet. 2003; 140: 99106.
  • 18
    Ichikawa D, Hashimoto N, Inazawa J, et al. Analysis of numerical aberrations in specific chromosome by fluorescence in situ hybridization as a diagnostic tool in breast cancer. Cancer. 1996; 77: 20642069.
  • 19
    Cooke HJ, Hindley J. Cloning of human satellite 3 DNA: different components are on different chromosomes. Nucleic Acids Res. 1979; 6: 31773197.
  • 20
    Ariyama T, Inazawa J, Ezaki T, et al. High-resolution cytogenetic mapping of the short arm of chromosome 1 with newly isolated 411 cosmid markers by fluorescence in situ hybridization: the precise order of 18 markers on 1p36.1 on prophase chromosomes and “stretched” DNAs. Genomics. 1995; 25: 114123.
  • 21
    Horii A, Han HJ, Shimada S, et al. Frequent patients with multiple primary cancers. Cancer Res. 1994; 54: 33733375.
  • 22
    Gyapay G, Morisette J, Vignal A, et al. The 1993–1994 Généthon human genetic linkage map. Nat Genet. 1994; 7: 246339.
  • 23
    Jones MH, Nakamura Y. Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chromosomes Cancer. 1992; 5: 8990.
  • 24
    Ensembl Genome Browser [database]. Hinxton, Cambridge, UK: The Wellcome Trust Sanger Institute. Available from URL: [accessed July 7, 2002].
  • 25
    Bello MJ, Vaquero J, de Campos JM, et al. Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int J Cancer. 1994; 57: 172175.
  • 26
    Husemann K, Wolter M, Buschges R, Bostrom J, Sabel M, Reifenberger G. Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. J Neuropathol Exp Neurol. 1999; 58: 10411050.
  • 27
    Tsujimoto T, Mochizuchi S, Iwadate Y, et al. The p73 gene is not mutated in oligodendrogliomas which frequently have a deleted region at chromosome 1p36.3. Anticancer Res. 2000; 20: 24952498.
  • 28
    Alonso ME, Bello MJ, Gonzalez-Gomez P, et al. Mutation analysis of the p73 gene in nonastrocytic brain tumours. Br J Cancer. 2001; 85: 204208.
  • 29
    Dong S, Pang JC, Poon W, et al. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol. 2001; 60: 808816.
  • 30
    Dong S, Pang JC, Hu J, Zhou L, Ng H. Transcriptional inactivation of TP73 expression in oligodendroglial tumors. Int J Cancer. 2002; 98: 370375.
  • 31
    Bello MJ, de Campos JM, Vaquero J, Kusak ME, Sarasa JL, Rey JA. High-resolution analysis of chromosome arm 1p alterations in meningioma. Cancer Genet Cytogenet. 2000; 120: 3036.
  • 32
    Praml C, Finke LH, Herfath C, Scjlag P, Schwab M, Amler L. Deletion mapping defines different regions in 1p34.2-pter that may harbor genetic information related to human colorectal cancer. Oncogene. 1995; 11: 135762.
  • 33
    Tsutsui H, Geltinger C, Murata T, et al. The DNA-binding and transcriptional activities of MAZ, a myc-associated zinc finger protein, are regulated by casein kinase II. Biochem Biophys Res Commun. 1999; 262: 198205.
  • 34
    Song J, Murakami H, Tsutsui H, et al. Structural organization and expression of the mouse gene for Pur-1, a highly conservative homolog of the human MAZ gene. Eur J Biochem. 1999; 259: 676683.
  • 35
    Ward AC, Smith L, de Koning JP, van Aesch Y, Touw IP. Multiple signals mediate proliferation, differentiation, and survival from the granulocyte colony-stimulating factor receptor in myeloid 32D cells. J Biol Chem. 1999; 274: 1495614962.
  • 36
    Koesters R, Adams V, Betts D, et al. Human eukaryotic initiation factor EIF2C1 gene: cDNA sequence, genomic organization, localization to chromosomal bands 1p34-p35, and expression. Genomics. 1999; 61: 210218.
  • 37
    Urban RJ, Bodenburg Y. PTB-associated splicing factor regulates growth factor-stimulated gene expression in mammalian cells. Am J Physiol Endocrinol Metab. 2002; 283: E794E798.
  • 38
    Smith JS, Tachibana I, Lee HK, et al. Mapping of the chromosome 19 q-arm glioma suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes Cancer. 2000; 29: 1625.
  • 39
    Saylors RL 3rd, Sidransky D, Friedman HS, et al. Infrequent p53 gene mutations in medulloblastomas. Cancer Res. 1991; 51: 47214723.
  • 40
    Saxena A, Clark WC, Robertson JT, Ikejiri B, Oldfield EH, Ali IU. Evidence for the involvement of potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytoma. Cancer Res. 1992; 52: 67166721.
  • 41
    Sasaki H, Zlastecu MC, Betensky RA, et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade “oligodendroglioma”. J Neuropathol Exp Neurol. 2002; 61: 5863.
  • 42
    Jeuken JWM, Sprenger SHE, Vermeer H, Kappelle AC, Boerman RH, Wesseling P. Chromosomal imbalances in primary oligodendroglial tumors and their recurrences: clues about malignant progression detected using comparative genomic hybridization. J Neurosurg. 2002; 96: 559564.
  • 43
    Bigner S, Matthews MR, Rasheed BKA, et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol. 1999; 155: 375386.
  • 44
    Nigro JM, Takahashi NA, Ginzinger DG, et al. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol. 2001; 158: 12531262.